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Background: It is known that being on antiretroviral therapy reduces the risk of HIV transmission through sex.
However it remains unknown what the absolute level of risk of transmission is in a person on ART with most recent
measured HIV plasma viral load< 50 c/mL in the absence of condom use. There are no data on risk of transmission
for anal sex in MSM when the index partner is on ART.
Methods/Design: The PARTNER study is an international, observational multi-centre study, taking place from 2010
to 2014 in which HIV serodifferent partnerships who at enrolment reported recently having had condom-less
vaginal or anal sexual intercourse are followed over time, with 4–6 monthly reporting of transmission risk behaviour
through a confidential self completed risk behaviour questionnaire and with 4–6 monthly HIV testing for the HIV
negative partner. The objective is to study (i) the risk of HIV transmission to partners, in particular in partnerships
that continue not to use condoms consistently and the HIV-positive partner is on therapy with a viral load< 50
copies/mL and (ii) why some partnerships do not use condoms, to describe the proportion who begin to adopt
consistent condom use, and factors associated with this. For any negative partner who becomes infected
phylogenetic analysis will be used following anonymisation of the samples to assess if transmission had been from
the HIV infected partner.
Discussion: This observational study will provide missing information on the absolute risk of HIV transmission for
both vaginal and anal sex when the index case is on ART with a VL< 50 copies/mL in the absence of condom use.
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It is consistently reported that a proportion of people with
diagnosed HIV do not always use a condom when having
sexual intercourse with partners of negative or unknown
HIVstatus. There are likely to be many reasons for this, and
these reasons may have changed over time. Increasingly,
one reason for not using condoms is likely to be due to the
person being on antiretroviral therapy with the plasma viral
load being< 50 copies/mL, and statements on the likely
reduced infectiousness of people in this situation have been
issued [1,2].* Correspondence: alison.rodger@ucl.ac.uk
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reproduction in any medium, provided the orThe HPTN 052 randomised controlled trial demon-
strated a reduction in HIV transmission risk in hetero-
sexual serodifferent couples due to ART use of 96% [3].
However as the HPTN 052 trial was performed in a
population where condom use was prevalent (96% of
those on ART reported regular condom use), the results
demonstrate the added benefit from ART in the context
of extensive condom use . Therefore it remains unknown
what the absolute level of risk of transmission is in a per-
son on ART with most recent measured plasma viral
load< 50 c/mL in the absence of condom use, particu-
larly amongst MSM. This is a key factor that will help to
determine whether more widespread and earlier use of
ART will result in a substantial reduction in HIV inci-
dence and hence be cost-effective, and is critical infor-
mation for counselling.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The PARTNER study set out to follow serodifferent partner-
ships who initially report recently having had condomless
sexual intercourse in order to study (i) the risk of HIV trans-
mission to partners, in particular in partnerships that con-
tinue not to use condoms consistently and the HIV-positive
partner is on therapy with a viral load< 50 copies/mL and
(ii) why some partnerships do not use condoms, to describe
the proportion who begin to adopt consistent condom use,
and factors associated with this.
Methods/Design
Study design and sample size
PARTNER is an observational study in which HIV sero-
discordant partnerships are followed over time, with 4–6
monthly reporting of transmission risk behaviour and
HIV testing for the HIV negative partner. Enrollment of
subjects will cease at end of 2013 and follow up will
cease in mid 2014 with enrolled partnerships followed
initially for 2 years. The study is co-ordinated jointly be-
tween UCL and the Copenhagen HIV Programme
(CHIP). The protocol (Version 1: 6th May 2010) and a
manual of operations were completed. Patient informa-
tion sheets and consent forms, clinical research forms
and study questionnaires were developed and all study
documents are available on line on the CHIP PARTNER
study website in 11 different languages (http://www.
cphiv.dk/PARTNER/StudyDocuments/tabid/440/Default.
aspx).
The sample size requirement was greater for the aim of
studying transmission than for the aim of studying the pro-
portion of partnerships that adopt consistent condom use
so sample size was based on that needed to study transmis-
sion. For studying HIV transmission, the primary aim is the
estimation of the transmission rate in partnerships which
are having condomless sex and where the HIV positive part-
ner has viral load< 50 copies/mL. If the true transmission
rate in this situation is< 1 per 1000 person years of con-
domless sex partnerships with viral load< 50, then with
2000 person years of observation with viral load< 50 there
is an 85% chance that the upper 95% confidence limit (i.e.
the upper bound on the transmission rate) for the transmis-
sion rate is< 0.0044 (i.e. 1 per 227 person years of condom-
less sex).We estimated that for 90% of included person time
the HIV positive partner will have viral load< 50 c/mL.
Thus we will need to accrue 2222 person years of follow-up
in order to accrue 2000 person years where the viral load is
< 50 c/mL. A proportion of partnerships will start to use
condoms for all sex (as they will continue to be advised to
do) so they will not be contributing person time of condom-
less sex.What this proportionwill be is unknown, but we as-
sume that this will be the case for one third of follow-up.
This means that we will require 3333 person years of follow-
up in total. Initially, 1666 partnerships will be identified,with the intention to follow them for up to 2 years. If for any
reason a partnership chooses/is unable to contribute for the
entire length of time, replacement will occur to achieve the
overall target of 3,333 person-years. Follow-up for all part-
nerships ceases when this target has beenmeet.
Recruitment and study procedures
Seventy two HIV clinics in the UK and throughout Eur-
ope are participating in the study (the number may ex-
pand further). Study sites are detailed on the PARTNER
study website (http://www.cphiv.dk/PARTNER/tabid/
406/Default.aspx). Any patient on ART (regardless of
VL) who was seen regularly for HIV care at a clinic and
who has a stable partner not known to be HIV-infected
and with whom he/she has had condomless sex in the
past 1 month (during which period the HIV negative
partner was aware of the HIV status of the HIV positive
partner) is eligible for inclusion in the study together
with his/her partner. Patients could enrol with more
than one partner, either concurrently or sequentially.
Partner informed consent included consent to provide a
blood sample if they become infected for phylogenetic
analysis, so that the virus could be compared with that
of index patient.
Subjects can self refer to the study. Study publicity in
the form of leaflets, posters, press releases and articles
were circulated to MSM press and national organiza-
tions. Eligible patients are identified in recruiting clinics
by asking patients about condomless sexual activity.
Patients are clearly informed about the risks of transmis-
sion by having condomless sex. Patients who reported
having an ongoing stable partner, who was not known to
be HIV-infected, with whom they had condomless sex in
the past month are asked if they would consider asking
their partner to come to the clinic to be enrolled in a
study with them. Patients and their partners were then
informed that the study is aiming to estimate the risk
that HIV is transmitted from one partner to the other.
The need for consistent condom use to avoid transmis-
sion is emphasised. The importance of the partner com-
mitting themselves to attending the clinic every 4 to
6 months to get tested for HIV (where possible a 4th
generation test was used which also picks up HIV anti-
gen and thus more sensitive to detecting recent infec-
tions before specific antibody is present), and to
complete a sexual risk behaviour questionnaire was
emphasised. If the patients and their partner both agree
to take part they signed separate informed consents,
which includes identification by name of the partner and
also that the HIV negative partner was aware of the HIV
positive status of their partner when they had condom-
less penetrative sex.
Both partners complete baseline questionnaires on risk
behaviour and then complete further risk behaviour
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negative partner tests for HIV at baseline and then again
at each 4 to 6 monthly visit. Viral load is measured in
patients at least 4 to 6 monthly. At each 4 monthly visit
patients are asked about penetrative sex with the partner.
If at any time the partner is found to be HIV-infected
they completed the risk behaviour questionnaire for the
final time and study follow-up ceased.
Data collection
Data is collected by online case-record-forms completed
by clinic staff and self completed paper risk behaviour
questionnaires from both HIV positive and HIV negative
partners. Questionnaire completion is done in a private
place by participants and when completed the question-
naire is placed in an envelope provided by staff and then
sent to Copenhagen HIV Programme [CHIP] (the study
co-ordinating centre) without being seen by clinic staff.
Participants are informed that clinic staff will not see
questionnaires.
All study forms contain the PARTNER study ID and
date of birth of the participant. No other patient identifi-
able information is included. The clinic keep a local log
linking participant name and date of birth with study ID.
The case Report Forms (CRFs) and risk behaviour ques-
tionnaires include the following forms and these can be
accessed online at the PARTNER study website.
1. Baseline risk behaviour in index patient (patient to
complete) – 3 versions (i) patient male, partner male
(ii) patient male, partner female, (iii) patient female,
partner male
2. Baseline risk behaviour in partner (patient to
complete) – 3 versions as above.
3. Baseline clinical and antiretroviral drug use status on
index patient (clinician/nurse to complete)
4. Follow-up risk behaviour in index patient (patient to
complete) – 3 versions as above.
5. Follow-up risk behaviour in partner (patient to
complete) – 3 versions as above.
6. Follow-up clinical and antiretroviral drug use status
on index patient (clinician/nurse to complete)
7. Partner infection form – risk behaviour (to be
completed by partner if partner becomes infected
with HIV) – 3 versions as above.
8. Partner infection form (to be completed by clinician/
nurse if partner becomes infected)
Phylogenetic analysis if a transmission occurs
For new infections, where possible, phylogenetic analysis
is to be used following anonymisation of the samples to
allow comparison of the HIV positive partner’s virus with
that of the newly infected partner, although the specific
partnership will not be identifiable. If the viruses are verydifferent by more than a certain percent of 3rd bases (e.g.
5%) it is to be concluded that transmission has not been
from the HIV infected partner. The anomymization
process means that partnerships cannot be told the
results of the virus comparison.
Data analysis plan and eligibility for time periods
(between HIV tests in HIV- partner) to be included in the
analysis
We are assessing the proportion of partnerships that begin
to adopt consistent condom use (i.e. reporting by both part-
ners of 100% of episodes of sexual intercourse in which a
condom was used) and factors associated with this using lo-
gistic regression. The primary analysis is estimation of the
rate of infection in partners per person year of condomless
sex partnership where the index patient has viral load <50
c/mL, excluding new infections that are shown to be phylo-
gentically distinct from the HIV positive partner’s virus; i.e.
transmission has not been from the HIV positive partner.
This will be calculated as the number of infections identified
at the end of eligible periods divided by the sum of the per-
son time over eligible periods. A “period” was defined as the
time between HIV tests in the HIV- partner. For a period to
be eligible the following criteria had to bemet: for all days in
the period, the most recently measured viral load value in
the HIV+partner must be< 50 copies/mL and have been
measured no more than 6 months previously. In addition, a
risk behaviour questionnaire, from the HIV negative part-
ner, reporting condomless anal or vaginal sex together with
the HIV+partner within the period, or the previous period,
was available. The entire duration of a period fulfilling these
criteria contributes to define the time spent at risk of trans-
mission. Examples of periods eligible and not eligible are
given in Figure 1.
In secondary analyses we will estimate (i) the rate of infec-
tion in partners per condomless sex act where index patient
has viral load< 50 c/mL, as opposed to per person year (this
was done by summing numbers of acts of anal and vaginal
intercourse over eligible periods) (ii) the rate of infection if
we replace 50 copies/mL by 200 copies/mL in the above def-
inition and (iii) the rate of transmission if we insist that the
next viral load value in the HIV positive partner after the
end of the period was also< 50 copies/mL, (iv) the rate of
transmission if we consider periods to be eligible if only oral
sex was reported and (v) the rate of transmission if we ignor
viral loadmeasures made on the HIV positive partner which
were within 4 weeks of the end of the period (because of the
lag time in obtaining a result).
Ethical committee review
The study is conducted according to the Declaration of
Helsinki in its current version (2004); the requirements
of Good Clinical Practice (GCP) as defined in EU GCP
Directive (2005/28/EC); Human Subject Protection and
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Figure 1 Examples of periods included and excluded for
primary analysis.
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tion, whichever affords greater protection of human
subjects. Prior to the initiation of the study at each clin-
ical research site, the protocol, all informed consent
forms and the participant information materials are
submitted to and approved by the site’s Ethics Commit-
tee (IRB or IEC). In the UK, the study was reviewed and
approved by the North West London REC 2 Ethics Com-
mittee (EC reference number 10/H0720/55). Ethics ap-
proval was obtained in-country for all other European
sites involved in the study. In addition any future amend-
ments to the study protocol will be submitted and
approved by each site’s Ethics Committee (IRB or IEC).
After approval, sites registered for the protocol beforescreening potential participants, and must also register for
any protocol amendments.
HIV transmission and risk of prosecution
All countries participating in the study have, or have
had, laws which potentially criminalize PLHIV. Such
criminalization may be for transmission, exposure or
non-disclosure, and for intentional, reckless or negligent
behavior [4]. The laws used may be general (i.e. HIV is
treated as a form of bodily harm), or HIV-specific. The
offences may be found either in a country’s Criminal or
Penal Code, or in its public health legislation. People
who have been convicted of HIV-related offences are
often sentenced to long periods of custodial punishment.
The fact that PLHIV may be, or have in the past been,
criminalized in countries participating in the study was a
central concern in developing its methodology and en-
suring its ethical approval. The confidentiality of all
study participants was protected in accordance with
GCP Guidelines and national regulations, and a review
of national criminal and public health laws was under-
taken. We recruited only in countries in which convic-
tions resulting from unprotected sex or HIV
transmission after disclosure of HIV-positive status had
not occurred, and was judged very unlikely to ever occur
in future. The key concern here was informed consent
and whether this provided a defence to allegations of ex-
posure or transmission in the participating countries. In
some European countries consent is available as a de-
fence only in very limited circumstances (in Norway, for
example, it is available only where the partners con-
cerned are effectively in a spousal relationship) and this
precluded their inclusion in the study [5]. In contrast,
some of the countries that are included are ones in
which the law in this area has either been reformed or
has suspended criminalization pending review. Thus, the
Netherlands now only contemplates the prosecution of
those who transmit HIV with malicious intent [6], while
Denmark has suspended its HIV-specific offence until an
analysis of its effectiveness has been completed [7]. It is
important to note that patients and their partners were
informed that the study was aiming to estimate the risk
that HIV is transmitted from one partner to the other
and why some partnerships do not use condoms, and
factors associated with this. The need for consistent con-
dom use to avoid transmission was emphasised at each
contact. If the patients and their partner both agreed to
take part they signed separate informed consents, which
included identification by name and date of birth of the
partner. All study participants signed all applicable
approved informed consent forms prior to any study-
related processes. The informed consent for HIV nega-
tive partners included explicit reference to the fact that
their partner has HIV and there is transmission risk,
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which follow-up was discontinued (including those in
which the reason for discontinuation of follow-up is in-
fection of the HIV negative partner) identifiers such as
study ID, clinic and day/month of birth, are deleted from
the central database, thus anonymizing the data on the
partnership. Thus, individuals who may have transmitted
HIV to their partners could not subsequently be identi-
fied through the central study database. Should a nega-
tive partner have become infected with HIV during the
study the analysis comparing the HIV positive partner’s
virus with that of the newly infected partner, is done only
after anonymization, and hence not linkable to the spe-
cific partnership.
Discussion
With the publication of the results of the HPTN 052 trial
there is now very strong evidence that virally suppressive
ART reduces infectiousness of people with HIV through het-
erosexual sex [2,3,8-12]. However, there is insufficient data
for transmission rates on ART in the absence of condom
use in heterosexuals and no data for rates of transmission
through anal sex in MSM which are likely to be different
than rates for vaginal sex. Ongoing observational studies
such as the PARTNER study will provide missing informa-
tion in several key areas. Firstly, to more precisely estimate
the absolute risk of HIV transmission using ART alone in
sero-different couples having condom-less vaginal sex with
suppressed VL on ART and to provide data on rates of
transmission for anal sex in serodifferent couples (including
MSM) which are likely to be different to vaginal sex.
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